5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic and metabolic hallmarks of SDH- and FH-deficient renal cell carcinomas
    Journal Article

    Yoo, A.; Tang, C.; Zucker, M.; Fitzgerald, K.; DiNatale, R. G.; Rappold, P. M.; Weiss, K.; Freeman, B.; Lee, C. H.; Schultz, N.; more...
    European Urology Focus (2022)

    Fulltext@MSK | Save
  • Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Milowsky, M.; Ramamurthy, C.; Mar, N.; McKay, R. R.; Friedlander, T.; Ferrario, C.; Bracarda, S.; George, S.; Moon, H.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
    Meeting Abstract

    Motzer, R. J.; Russo, P.; Gruenwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O. A.; Buti, S.; Barthelemy, P.; Goh, J. C. H.; Ye, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
    Meeting Abstract

    Choueiri, T. K.; Powles, T. B.; Albiges, L.; Burotto, M.; Szczylik, C.; Zurawski, B.; Riuz, E. Y.; Maruzzo, M.; Zaizar, A. S.; Fein, L. E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
    Meeting Abstract

    Aggarwal, R.; Heller, G.; Hillman, D.; Xiao, H.; Picus, J.; Wang, J.; Taplin, M. E.; Dorff, T.; Appleman, L. J.; Weckstein, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)
    Meeting Abstract

    Koshkin, V. S.; Powles, T. B.; Iyer, G.; Loriot, Y.; Drakaki, A.; Martinez, I. D.; De Santis, M.; Retz, M.; Jain, R. K.; Chan, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study
    Meeting Abstract

    De Wit, R.; Vaughn, D. J.; Fradet, Y.; Fong, L.; Vogelzang, N. J.; Duran, M. A. C.; Necchi, A.; Petrylak, D. P.; Gerritsen, W. R.; Gurney, H. P.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial
    Meeting Abstract

    Necchi, A.; Bajorin, D. F.; Tomita, Y.; Ye, D.; Agerbaek, M.; Enting, D.; Peer, A.; Milowsky, M.; Kobayashi, K.; Grimm, M. O.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Meeting Abstract

    Porta, C. G.; Eto, M.; Motzer, R. J.; De Giorgi, U. F. F.; Buchler, T.; Basappa, N. S.; Vidal, M. J. M.; Tjulandin, S.; Park, S. H.; Melichar, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Association between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced first-line (1L) renal cell carcinoma (aRCC): Exploratory analyses from CheckMate 9ER (CM 9ER)
    Meeting Abstract

    Cella, D.; Porta, C. G.; Hamilton, M.; Ejzykowicz, F.; Blum, S. I.; Ivanescu, C.; Rodriguez, C. S.; Choueiri, T. K.; Motzer, R. J.
    Annals of Oncology (2022)

    Fulltext@MSK | Save